NO20073071L - Benzotiazolformuleringer og anvendelse av disse - Google Patents

Benzotiazolformuleringer og anvendelse av disse

Info

Publication number
NO20073071L
NO20073071L NO20073071A NO20073071A NO20073071L NO 20073071 L NO20073071 L NO 20073071L NO 20073071 A NO20073071 A NO 20073071A NO 20073071 A NO20073071 A NO 20073071A NO 20073071 L NO20073071 L NO 20073071L
Authority
NO
Norway
Prior art keywords
benzothiazole
formulations
relates
pharmaceutical formulations
benzothiazole formulations
Prior art date
Application number
NO20073071A
Other languages
English (en)
Inventor
Jean-Pierre Gotteland
Pierandrea Esposito
Mario Maio
Daniela Chicco
Luca Donati
Andrea Leonardi
Stefania Bertero
Pascale Gaillard
Isabelle Jeanclaude-Etter
Simone Grandolini
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20073071L publication Critical patent/NO20073071L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

Den foreliggende oppfinnelsen angår makrogolglyserid farmasøytiske formuleringer som inneholder benzotiazolderivater. Mer spesielt angår oppfinnelsen benzotiazolstearoylmakrogol farmasøytiske formuleringer, fremgangsmåter for deres fremstilling og anvendelse av disse.
NO20073071A 2004-11-17 2007-06-15 Benzotiazolformuleringer og anvendelse av disse NO20073071L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04105843 2004-11-17
US62899804P 2004-11-18 2004-11-18
PCT/EP2005/056020 WO2006053882A2 (en) 2004-11-17 2005-11-16 Benzothiazole formulations and use thereof

Publications (1)

Publication Number Publication Date
NO20073071L true NO20073071L (no) 2007-06-15

Family

ID=36407499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073071A NO20073071L (no) 2004-11-17 2007-06-15 Benzotiazolformuleringer og anvendelse av disse

Country Status (20)

Country Link
EP (1) EP1812072B1 (no)
JP (1) JP5144271B2 (no)
KR (1) KR101337726B1 (no)
AR (1) AR052139A1 (no)
AT (1) ATE411817T1 (no)
AU (1) AU2005305880B2 (no)
BR (1) BRPI0517782A (no)
CA (1) CA2585316C (no)
CY (1) CY1108711T1 (no)
DE (1) DE602005010604D1 (no)
DK (1) DK1812072T3 (no)
EA (1) EA011614B1 (no)
ES (1) ES2315931T3 (no)
HR (1) HRP20080544T3 (no)
IL (1) IL182955A (no)
NO (1) NO20073071L (no)
PL (1) PL1812072T3 (no)
PT (1) PT1812072E (no)
SI (1) SI1812072T1 (no)
WO (1) WO2006053882A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613042A2 (pt) * 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
EP2298286B8 (en) * 2009-09-18 2017-08-09 SiTec PharmaBio SL Process for dewatering of product powders
EP2510924B1 (en) * 2009-12-08 2014-10-08 IL Hwa Co., Ltd SOLID DISPERSIONS CONTAINING 20-O-ß-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
EP2560618A1 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH Melt-granulated fingolimod
CA2797042A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod in the form of a solid solution
CN113354550B (zh) * 2021-05-28 2023-04-11 吉林大学 一种氨甲苯酸的制备方法
KR20230164862A (ko) * 2022-05-26 2023-12-05 연세대학교 산학협력단 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69811233T2 (de) * 1997-10-27 2003-11-20 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
JP4570357B2 (ja) * 2001-07-06 2010-10-27 ライフサイクル ファーマ エー／エス 制御された凝集
JP4589002B2 (ja) * 2001-12-07 2010-12-01 メルク セローノ ソシエテ アノニム 強皮症の治療のためのベンザゾール誘導体
WO2004061433A1 (en) * 2002-12-30 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
RS51407B (en) * 2002-04-25 2011-02-28 Laboratoires Serono Sa PIPERAZINE BENZOTIASOLS AS AGENTS FOR TREATMENT OF CERABRAL ISCHEMICAL OR CNS DISORDERS

Also Published As

Publication number Publication date
KR101337726B1 (ko) 2013-12-12
DK1812072T3 (da) 2008-12-01
CA2585316A1 (en) 2006-05-26
EP1812072B1 (en) 2008-10-22
HRP20080544T3 (en) 2008-12-31
KR20070092963A (ko) 2007-09-14
EA200701072A1 (ru) 2007-10-26
BRPI0517782A (pt) 2008-10-21
CY1108711T1 (el) 2014-04-09
SI1812072T1 (sl) 2009-04-30
JP2008520624A (ja) 2008-06-19
ATE411817T1 (de) 2008-11-15
IL182955A (en) 2011-05-31
AR052139A1 (es) 2007-03-07
IL182955A0 (en) 2007-08-19
EA011614B1 (ru) 2009-04-28
AU2005305880B2 (en) 2010-08-26
PT1812072E (pt) 2008-11-04
EP1812072A2 (en) 2007-08-01
WO2006053882A3 (en) 2006-09-08
ES2315931T3 (es) 2009-04-01
CA2585316C (en) 2013-06-25
DE602005010604D1 (de) 2008-12-04
PL1812072T3 (pl) 2009-04-30
JP5144271B2 (ja) 2013-02-13
WO2006053882A2 (en) 2006-05-26
AU2005305880A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
NO20071095L (no) Hittil ukjente tiofenderivater
NO20090628L (no) Pyridizinon derivativater
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20064584L (no) Tetrahydropyridoindolderivater
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
NO20090295L (no) Substituerte heteroarylderivater
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
NO20075918L (no) Substituerte pyrrolo-pyridiner, forbindelser inneholdende disse, fremgangsmate for deres fremstilling og anvendelse derav
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20082793L (no) Nye tiofenderivater
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
NO20081160L (no) Benzimidazoltiofen forbindelser
GEP20094784B (en) Sustained release pharmaceutical formulations
DK1670458T3 (da) 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
NO20084821L (no) Formuleringer og metoder for celleimaging og terapi
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application